Glucose or Insulin, Which Is the Culprit in Patients with COVID-19 and Diabetes?

Cell Metab. 2021 Jan 5;33(1):2-4. doi: 10.1016/j.cmet.2020.11.015. Epub 2020 Nov 24.

Abstract

Patients with a metabolic syndrome (overweight, diabetes, hypertension, and dyslipidemia) have a particularly bad outcome if infected with SARS-CoV-2. Yu et al. (2020) suggest that insulin therapy itself may promote fatality in patients with COVID-19 and diabetes.

Publication types

  • Review

MeSH terms

  • COVID-19 / complications
  • COVID-19 / metabolism*
  • COVID-19 Drug Treatment
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / metabolism*
  • Female
  • Glucose / metabolism*
  • Humans
  • Inflammation / complications
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Insulins / adverse effects
  • Insulins / metabolism*
  • Insulins / therapeutic use
  • Male
  • SARS-CoV-2 / metabolism*

Substances

  • Insulins
  • Glucose